Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Brodowicz, Thomas; Krzakowski, Maciej; Zwitter, Matjaž; Tzekova, Valentina; Ramlau, Rodryg; Ghilezan, N.; Ciuleanu, Tudor-Eliade; Čučević, Branka; Gyurkovits, K.; Ulsperger, Ernst; Jassem, Jacek; Grgić, Mislav; Saip, Pınar; Szilasi, Mária; Wiltschke, Christoph; Wagnerová, M; Oskina, N. А.; Soldatenkova, Victoria; Zielinski, Christoph; Wenczl, M.

doi:10.1016/j.lungcan.2006.01.006

Cited by 287 publications

(191 citation statements)

References 24 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…6 Along these lines, promising results were recently presented by Belani et al 7,8 suggesting that weekly paclitaxel maintenance after 6 cycles of carboplatin/paclitaxel may indeed prolong survival with minimal additional toxicity. Similar results were obtained by Brodowicz et al 9 with gemcitabine maintenance therapy after initial therapy with gemcitabine plus cisplatin. Maintenance chemotherapy was feasible and produced significantly longer time to progression compared with best supportive care alone.…”

Section: Regimen and 4 Cyclessupporting

confidence: 87%

Sequential chemotherapy in nonsmall‐cell lung cancer

Ceribelli

Pino²,

Milella³

et al. 2007

Cancer

View full text Add to dashboard Cite

Objective: Preterm infants exhibit chronic deficits in white matter (WM) and cortical maturation. Although fetal infection/inflammation may contribute to WM pathology, the factors contributing to cortical changes are largely unknown. We examined the effect of fetal lipopolysaccharide (LPS) exposure on WM and cortical development as assessed by magnetic resonance imaging (MRI), electroencephalography (EEG), and histopathology in fetal sheep at preterm human equivalent age. Methods: LPS was administered to fetal sheep at 102.5 ± 0.5 days of gestation. Continuous biophysical recordings were analyzed for 10 days after LPS. At postmortem, measurement of cerebral WM and cortical tissue volumes was achieved by stereological techniques. Specific effects of LPS on MRI‐assessed T1‐weighted and T2‐weighted images, and immunohistochemical expression of oligodendrocytes, proliferating cells, cortical NeuN‐positive and Nurr1‐positive neurons (subplate marker), and cell death mechanisms were examined. Results: We observed reductions in WM (∼21%; LPS, 1.19 ± 0.04 vs control, 1.51 ± 0.07cm3; p < 0.001) and cortical (∼18%; LPS, 2.34 ± 0.10 vs control, 2.85 ± 0.07cm3; p < 0.001) volumes, associated with overt and diffuse WM injury, T1‐/T2‐weighted signal alterations, and reduced numbers of WM oligodendrocytes (LPS, 485 ± 31 vs control, 699 ± 69 cells/mm2; p = 0.0189) and NeuN‐positive (LPS, 421 ± 71 vs control 718 ± 92 cells/mm2; p = 0.04) and Nurr1‐positive (control, 2.5 ± 0.6 vs LPS, 0.6 ± 0.1 cells/mm2; p = 0.007) cortical neurons after LPS. Moreover, there was loss of the normal maturational increase in cortical EEG amplitude, which correlated with reduced cortical volumes. Interpretation: Fetal exposure to LPS prior to myelination onset can impair both white matter and cortical development in a preclinical large animal model, supporting a role for maternal/fetal infection in the pathogenesis of preterm brain injury. ANN NEUROL 2011

show abstract

Section: Regimen and 4 Cyclessupporting

confidence: 87%

Sequential chemotherapy in nonsmall‐cell lung cancer

Ceribelli

Pino²,

Milella³

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…However, this is somewhat counterbalanced by the fact that there was a greater proportion of patients classified as ECOG performance status 0 in the current study when compared to those in the PARAMOUNT study (59% PS 0 in current study; 32% PS 0 in PARAMOUNT study). Previous studies have suggested that patients with advanced NSCLC and poor ECOG performance status gain little benefit from maintenance gemcitabine [13,14]. The current study provides evidence that increasing ECOG performance status also translates into reduced benefit from pemetrexed continuation maintenance in advanced NSCLC.…”

Section: Discussionsupporting

confidence: 53%

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung

Kim

Kinmond

Gilani

et al. 2015

Forum of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Brodowicz et al showed that maintenance therapy with gemcitabine resulted in a longer median time to progression (6.6 versus 5.0 months; P < 0.001) without any significant improvement in median OS (13 versus 11 months; P = 0.195). 49 However a preplanned subgroup analysis revealed that in those with a Karnofsky performance status (KPS) score of greater than 80, the median survival doubled (25.3 versus 12.2 months). Gemcitabine maintenance following gemcitabine carboplatin combination reported by Belani et al was a negative trial for PFS (P 0.57) and OS (P 0.83), possibly because 66% of the patients had PS 2 and only 34% had a PS 0-1.…”

Section: -39mentioning

confidence: 99%